Colinz Laboratories
53.50
+3.24(+6.45%)
Market Cap₹24.48 Cr
PE Ratio49.76
IndustryHealthcare
Company Performance:
1D+6.45%
1M+30.84%
6M+20.33%
1Y-23.70%
5Y+274.91%
View Company Insightsright
More news about Colinz Laboratories
03Nov 25
Colinz Laboratories Reports Q2 FY2026 Results: Revenue Dips, Profit Rises
Colinz Laboratories Limited, a pharmaceutical formulations manufacturer, announced its Q2 FY2026 results. Revenue decreased to ₹138.80 lakhs from ₹156.61 lakhs in Q1, but net profit increased to ₹14.05 lakhs from ₹11.92 lakhs. Half-year revenue stood at ₹295.41 lakhs with a net profit of ₹25.97 lakhs. The company's total assets reached ₹1,212.62 lakhs with strong liquidity of ₹742.18 lakhs in cash and equivalents. Despite revenue decline, improved profitability suggests effective cost management.
14Oct 25
Colinz Laboratories Seeks Shareholder Approval for Rs 6 Crore Asset Sale
Colinz Laboratories Ltd plans to sell two key assets valued at a minimum of Rs 6.00 crores, subject to shareholder approval via postal ballot. The assets include a pharmaceutical manufacturing factory in Sinnar, Nashik (valued at Rs 3.00 crores) and office premises in Mumbai (valued at Rs 3.00 crores). The sale aims to address high costs of compliance with new WHO norms and infrastructure limitations. The company is considering setting up a new factory in Gujarat or acquiring a ready-made WHO-compliant facility with the sale proceeds. Shareholder voting period is set from October 15 to November 14, 2025.
31Jul 25
Colinz Laboratories Approves Q1 Results, Appoints New Directors
Colinz Laboratories Limited approved unaudited Q1 FY2025-26 results and made significant appointments. Mr. Swapnil Jayeshbhai Madiyar recommended as Non-Executive Director and Mr. N. K. Menon for reappointment as Whole Time Director and CEO. The company scheduled its 39th AGM for September 30, 2025, via video conference. Appointments for Secretarial and Internal Auditors were also made. E-voting for AGM set from September 27 to 29, 2025.
31Jul 25
Colinz Laboratories Approves Q1 Results, Appoints New Directors, and Sets AGM Date
Colinz Laboratories Limited approved unaudited Q1 financial results for the quarter ended June 30, 2025. The Board recommended appointing Mr. Swapnil Jayeshbhai Madiyar as Non-Promoter, Non-Executive Director and reappointing Mr. N. K. Menon as Whole Time Director and CEO. The 39th AGM is scheduled for September 30, 2025, via video conference. The company appointed Secretarial and Internal Auditors for FY 2025-26. E-voting for eligible shareholders will be available from September 27 to 29, 2025.
31Jul 25
Colinz Laboratories Approves Q1 Results, Appoints New Directors
Colinz Laboratories Limited approved unaudited Q1 FY2025-26 results and made significant leadership changes. The Board recommended Mr. Swapnil Jayeshbhai Madiyar as Non-Executive Director and reappointed Mr. N. K. Menon as Whole Time Director and CEO. The 39th AGM is scheduled for September 30, 2025, via video conference. The company also appointed secretarial and internal auditors for FY2025-26.
Colinz Laboratories
53.50
+3.24
(+6.45%)
1 Year Returns:-23.70%
Industry Peers
Sun Pharmaceutical
1,719.70
(-0.03%)
Divis Laboratories
6,392.50
(+0.50%)
Torrent Pharmaceuticals
3,850.00
(+0.73%)
Cipla
1,511.30
(+1.26%)
Dr Reddys Laboratories
1,271.40
(+0.44%)
Lupin
2,109.50
(+1.40%)
Zydus Life Science
914.35
(+1.43%)
Mankind Pharma
2,196.50
(+2.04%)
Aurobindo Pharma
1,183.00
(-0.28%)
Alkem Laboratories
5,506.50
(+0.69%)